Literature DB >> 8131092

Management of brain metastases.

L M DeAngelis1.   

Abstract

Brain metastases usually develop in patients with disseminated systemic disease. Effective palliation is available for the vast majority of patients with brain metastases, but many will die within 6 months, usually from progressive systemic tumor. However, in a substantial proportion of patients, a vigorous therapeutic approach using surgery, radiotherapy, and possibly chemotherapy leads to years of productive life. Recurrent brain metastases can often be retreated using newer techniques of brachytherapy and stereotactic radiosurgery as well as conventional treatments. Brain metastases do not necessarily mean imminent death for every patient, and physicians can now offer patients a growing range of therapeutic options. Furthermore, attention to symptomatic therapies can improve the quality of life for all patients, even those whose survival will be relatively short.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8131092     DOI: 10.3109/07357909409024871

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  8 in total

1.  Metastatic Disease of the Nervous System.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

Review 2.  Radiation, chemotherapy, and symptom management in cancer-related cognitive dysfunction.

Authors:  Christopher Loiselle; Jason Rockhill
Journal:  Curr Pain Headache Rep       Date:  2009-08

Review 3.  Brain metastases: 1995. A brief review.

Authors:  J B Posner
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

Review 4.  Brain metastases: treatment options to improve outcomes.

Authors:  Phillip Davey
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Management of brain metastases.

Authors:  John G Stewart; Stephen M Sawrie; Asim Bag; Xiaosi Han; John B Fiveash
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

6.  Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial.

Authors:  Xiao-Xiao Dinglin; Yan Huang; Hui Liu; Yin-Duo Zeng; Xue Hou; Li-Kun Chen
Journal:  J Neurooncol       Date:  2013-02-19       Impact factor: 4.130

7.  Steroid management in newly diagnosed glioblastoma.

Authors:  Mariel B Deutsch; Katherine S Panageas; Andrew B Lassman; Lisa M Deangelis
Journal:  J Neurooncol       Date:  2013-03-06       Impact factor: 4.130

8.  A Single-Institution Analysis of 126 Patients Treated with Stereotactic Radiosurgery for Brain Metastases.

Authors:  Kevin B Harris; Melanie R Corbett; Henry Mascarenhas; Kenneth Stuart Lee; Hyder Arastu; Clinton Leinweber; Andrew W Ju
Journal:  Front Oncol       Date:  2017-05-12       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.